The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022LEARN-ATMP – Using the Patient Voice to Develop a Framework for Accessible ATMP Trials
Study Rationale: New therapies for Parkinson’s disease (PD) that involve the use of cells or genes — sometimes called advanced therapy medicinal products (ATMP) — are being developed and tested in...
-
Accelerating the Translation of Parkinson's Disease Therapies, 2022Esya PD360: A Multi-parametric Platform for Establishing a Novel Lysosome-based Biomarker and Identifying Therapeutic Interventions for Parkinson’s Disease
Study Rationale: Lysosomes are sub-cellular compartments responsible for clearing proteins that are prone to aggregation, a process called autophagy. Dysfunctional lysosomes with increased acidity and...
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Validation of a Novel Mitochondrial Drug Target for Parkinson’s Disease
Study Rationale: Mitochondria provide cells with energy, but they also help regulate the flow of large amounts of calcium ions that flood neurons when they are active. In Parkinson’s disease (PD)...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Evaluating an Insulin-degrading Enzyme as a Novel Therapeutic Target for Parkinson’s Disease
Study Rationale: In Parkinson’s disease (PD), the clumping of the protein alpha-synuclein in the brain causes the death of neurons. Recent studies have shown that the insulin-degrading enzyme (IDE)...
-
Research Grant, 2022Evaluation of a Monitoring System Based on a Wearable Sensor for Improving Swallowing and Saliva Control in Parkinson’s Disease
Study Rationale: Trouble with swallowing and increased drooling are common issues for people with Parkinson’s disease (PD). These oral symptoms occur in up to 80% of cases. Our prior work showed that...
-
Research Grant, 2022Performing a First-In-Human Study of a Retinal Tracer For Alpha-synuclein in Parkinson's Disease
Study Rationale: Like the brain, the retina is part of the central nervous system. We therefore aim to develop a new and simple way to diagnose Parkinson’s disease (PD) via examination of the eye. To...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.